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Abstract
Background: The emergence and spread of antibiotic resistant micro-organisms is a global concern, which is
largely attributable to inaccurate prescribing of antibiotics to patients presenting with non-bacterial infections. The
use of ‘omics’ technologies for discovery of novel infection related biomarkers combined with novel treatment
algorithms offers possibilities for rapidly distinguishing between bacterial and viral infections. This distinction can be
particularly important for patients suffering from lower respiratory tract infections (LRTI) and/or sepsis as they represent
a significant burden to healthcare systems. Here we present the study details of the TAILORED-Treatment study, an
observational, prospective, multi-centre study aiming to generate a multi-parametric model, combining host and
pathogen data, for distinguishing between bacterial and viral aetiologies in children and adults with LRTI and/or sepsis.
Methods: A total number of 1200 paediatric and adult patients aged 1 month and older with LRTI and/or sepsis or a
non-infectious disease are recruited from Emergency Departments and hospital wards of seven Dutch and Israeli
medical centres. A panel of three experienced physicians adjudicate a reference standard diagnosis for all patients (i.e.,
bacterial or viral infection) using all available clinical and laboratory information, including a 28-day follow-up
assessment. Nasal swabs and blood samples are collected for multi-omics investigations including host RNA and
protein biomarkers, nasal microbiota profiling, host genomic profiling and bacterial proteomics. Simplified data is
entered into a custom-built database in order to develop a multi-parametric model and diagnostic tools for
differentiating between bacterial and viral infections. The predictions from the model will be compared with the
consensus diagnosis in order to determine its accuracy.
Discussion: The TAILORED-Treatment study will provide new insights into the interplay between the host and micro-
organisms. New host- or pathogen-related biomarkers will be used to generate a multi-parametric model for
distinguishing between bacterial and viral infections. This model will be helpful to better guide antimicrobial therapy
for patients with LRTI and sepsis. This study has the potential to improve patient care, reduce unnecessary antibiotic
prescribing and will contribute positively to institutional, national and international healthcare economics.
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Background
The burden of antibiotic misuse
Antibiotics are the most prescribed class of drugs world-
wide [1]. However, 30–50% of antibiotics are estimated
to be prescribed inappropriately, making antibiotics also
the most misused drug class [1–5]. Antibiotic overuse,
i.e. prescribing antibiotics to treat a non-bacterial dis-
ease, is a serious problem. For example, in the US over
80 million antibiotic prescriptions are given annually for
viral infections in the outpatient setting [6]. This may
cause the emergence of adverse events (AEs) such as al-
lergic reactions and antibiotic-associated diarrhoea [7].
Importantly, antibiotic overuse has been linked to the
emergence of resistant strains of bacteria, by the Center
for Disease Control considered as “one of the world’s most
pressing health problems in the 21st century” [8, 9]. Annu-
ally, 23,000 deaths due to resistant bacteria are expected
in the US alone [8, 10]. Resistant bacteria are projected to
cause over 10 M annual deaths worldwide by 2050, sur-
passing cancer as the leading cause of death [8, 11]. A sec-
ond type of antibiotic misuse is underuse, i.e. delayed or
no antibiotic treatment in case of a bacterial disease, from
which a patient could have benefited [12–17]. Although
reducing the risk of antibiotic-related AEs [18, 19], under-
use of antibiotics may lead to a prolonged disease duration
and an increased rate of complications that could have
been avoided with early antimicrobial treatment [19–21].
For example, up to 15–40% of adult patients hospitalized
for bacterial pneumonia in the US receive delayed or
no antibiotic treatment [14, 15]. Finally, applying the
wrong antibiotic spectrum to treat a bacterial disease
is the third type of antibiotic misuse. For example,
administering third generation cephalosporins instead
of macrolides to treat a respiratory infection caused
by atypical bacteria.
Health economics consequences
Antibiotic overuse has also several health economics
consequences. For instance, the annual cost of unneces-
sary antibiotic prescriptions for adult respiratory
infections in the US is estimated to be $1.1 billion [22].
In addition, there are also indirect costs, including the
costs of treating preventable antibiotic-related AEs and
the costs of prolonged hospital stay as a result of AEs.
Lastly, are the costs related to the emergence of
antibiotic-resistant bacterial strains. The cost of treating
patients with antibiotic-resistant bacteria is estimated at
$16–26 billion annually in the US [23–25] and over €1.5
billion in the EU [26]. The health economics conse-
quences of underuse of antibiotics include the costs of
treating preventable complications and a prolonged dis-
ease duration resulting from a delayed or no antibiotic
treatment [19–21].
Antibiotics in respiratory tract infections and sepsis
Respiratory tract infections are one of the most common
causes of hospital and outpatient visits in the EU, com-
prising 1 out of 3 admissions annually [9]. In patients
with mild respiratory tract infections, over prescription
of antibiotics in general and prescription of broad
spectrum antibiotics are large problems. Broad spectrum
antibiotics account for approximately half of all anti-
biotic prescribing for children with acute RTI [27], with
the above mentioned consequences [8]. Sepsis-related
hospital admissions are less frequent but represent a
significant burden to healthcare systems in terms of
adverse patient outcomes and the need for rapid, but ef-
fective, intervention strategies [28]. In septic patients the
key clinical challenge is to ensure that the correct anti-
microbial treatment is administered, and that this ther-
apy is administered as soon as possible [29].
Limitations of current diagnostic tools
Although the current diagnostic tools for facilitating
appropriate use of antibiotics (such as culture-, PCR-,
and immunoassay-based) may be valuable in some clin-
ical situations, they have major limitations (Fig. 1). First,
existing diagnostic tools often require hours to days to
provide information, whereas physicians need to decide
whether to prescribe antibiotics within shorter time pe-
riods. Second, available diagnostic technologies usually
require direct sampling of the pathogen. Such sampling
is often not feasible if the infection site is inaccessible
(e.g., pneumonia, sinusitis, middle-ear infection, etc.). A
third limitation is that available technologies usually
search for the presence of specific bacteria or viruses.
However, many types of bacteria and viruses could be
present as part of the natural flora without causing an
infection. For example, the important respiratory tract
pathogenic bacteria S. pneumoniae is also part of the
upper respiratory tract natural flora in up to 68% and 15%
of healthy children and adults, respectively [30] and re-
spiratory viruses were detected in 35.4% of a-symptomatic
children [31]. Finally, diagnostic solutions that were devel-
oped for detection of a specific pathogenic strain, often fail
to detect the constantly evolving and emerging strains of
the same family of pathogens, for example rapid Influenza
tests showed low sensitivity, 45%, during the 2009 H1N1
influenza A viral outbreak [32]. These limitations lead to a
‘diagnostic gap’, which in turn often leads physicians to
either over-prescribe (e.g., ‘just-in-case’ approach) or
under-prescribe (e.g., ‘watchful waiting’ approach) antibi-
otics [18–20], both of which adversely influence patient
care and health economics.
The TAILORED-treatment project
The health and health economics consequences of anti-
biotic misuse highlight the need for a diagnostic tool
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that would help physicians to use antibiotics appropri-
ately. Ideally, this diagnostic tool should provide a
diagnosis that can accurately and rapidly differentiate
between bacterial and viral infections. However, as previ-
ously described, current diagnostic tools are often inad-
equate (Fig. 1). Therefore, the TAILORED-Treatment
consortium was established to develop new tools aimed
at increasing the effectiveness of antibiotic therapy,
reduce adverse events, and limit the emergence of anti-
microbial resistance in children and adults. In reality,
targeted antimicrobial therapy can most effectively be
achieved by utilizing personalized data to facilitate a tai-
lored and optimized approach to individual patient treat-
ment. This can best be achieved by utilizing knowledge
gained from both host-centred and pathogen-centred
parameters during health and disease. Unfortunately,
these parameters have traditionally, tended to be mea-
sured independently, and used on an ad hoc basis
without careful integration for the best treatment of the
patient. However, recent advances in the development of
high-throughput and sensitive molecular-based tech-
nologies, improved databases, and bioinformatics ana-
lysis tools, rapidly enabling that the goal of personalized
medicine and treatment can be reached. Unfortunately,
however, there currently exists a ‘technological gap’
between recent state-of-the-art methodologies (for ex-
ample with respect to gaining new insights into novel
host-pathogen interactions) and laboratory-to-bedside
results to benefit patients, physicians and society as a
whole [33]. The observational TAILORED-Treatment
project is designed to bridge this technological gap in
order to generate novel insights and innovations that are
readily exploitable in the field of personalized medicine
and infectious diseases.
Study objectives
Primary objective
To develop a novel multi-parametric diagnostic model for
the management of patients with LRTI and/or sepsis that
is based on novel pathogen- and host-related factors.
Secondary objectives
1. Identify individual as well as sets of blood host
biomarkers for differentiating between bacterial,
and viral aetiologies and determine the sensitivity
and specificity of these biomarkers in distinguishing
between the different infection types;
2. Identify individual as well as sets of blood host
biomarkers for differentiating between bacterial
Fig. 1 Limitations of current diagnostic tools
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subtypes, namely Gram positive, Gram negative and
atypical bacteria;
3. Characterize the temporal dynamics of the host-
pathogen interactions based on multiple sampling
before and during antimicrobial treatment;
4. Characterize the respiratory microbiome in patients
presenting with LRTI and/or sepsis;
5. Develop a mass spectrometry based, rapid detection
technique for identification of microbial pathogens
and antimicrobial resistances in clinical samples;
6. Develop a personalized treatment algorithm for
tailored antimicrobial therapy that integrates
clinical, molecular and biochemical data;
7. Define genetic mechanisms underlying the
differential host response between patients with
viral versus bacterial infection.
Methods
General study design
In this prospective, multi-centre, observational study, an
expected total number of 1200 paediatric and adult pa-
tients aged 1 month and older with suspected LRTI and/
or sepsis or a non-infectious disease are recruited, in
order to develop a diagnostic model to differentiate be-
tween bacterial and viral infections. The study will gen-
erate a model for patients with LRTI and a separate
model for patients with sepsis. The prediction of the
model obtained from each patient will be compared with
a consensus diagnosis by a panel of three experts in
order to determine its accuracy (Fig. 2). The study is
a non-interventional study, and therefore, the diag-
nostic prediction of the model will not be used for
any clinical or diagnostics decision making. Local data
Fig. 2 Schematic diagram of the study workflow
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monitor plans were used and executed by local, inde-
pendent monitors.
Study participants
Patients aged 1 month and older that attend the Emer-
gency Department (ED) and hospital wards of seven
Dutch and Israel medical centres (secondary and ter-
tiary) due to a suspected LRTI and/or sepsis that agree
(or their legal guardians agrees) to sign an informed con-
sent and meet the inclusion criteria and none of the ex-
clusion criteria (Table 1), are eligible to participate in the
study. Informed consent is asked by the study team (i.e.
research nurses or medical doctor). Sepsis criteria are de-
fined according to published criteria [34]. Patients receive
care as usual. The non-infectious disease group include
patients with clinical signs of a non-infectious disease.
Data/sample collection
Clinical data
Clinical evaluation and management is performed ac-
cording to standard institutional procedures (Fig. 2).
Collected clinical data, includes demographics, medical
history, clinical symptoms, physical examination, disease
course, laboratory measurements, as well as more ad-
vanced diagnostic information including microbiological
(including an additional multiplex PCR), and serological
investigations. A follow-up phone call 28-day after re-
cruitment, defines the end of follow-up and generates
data to be used by the expert panel (e.g. maximum dis-
ease severity, total use of antibiotics, Additional file 1).
Sample collection
For study purposes two blood samples, two nasal swabs
and (in case of diarrhoea) a stool sample are collected
(Fig. 2). Blood and nasal swabs sampling at two sampling
points (at inclusion and after 3–5 days) is performed in
hospitalized Dutch children in order to monitor the
temporal dynamics of the host-pathogen interactions.
One nasal swab sample (Universal Transport Medium,
Copan, USA) is used for PCR based microbiological
investigations performed for the establishment of patient
diagnosis (only at inclusion). The PCR results are included
in the eCRF and are available to the TAILORED-Treatment
expert panel while determining the diagnosis of the patient
(Fig. 2). The second nasal swab is collected in Transport
Medium suitable for bacterial culturing (e-swab, Liquid
Amies Medium, Copan), this sample is used for respiratory
microbiome investigations and to develop a rapid detection
technique for identification of microbial pathogens and
antimicrobial resistances, based on mass spectrometry and
proteomics for discovery of peptide biomarkers. Serum
samples are used for different proteomic measurements,
leukocytes are isolated for discovery of RNA-based bio-
markers. Following RNA isolation, remaining DNA is used
for GWAS studies. GWAS analyses is performed in the
Netherlands, as Institutional review board (IRB) approval
for genetic testing is not obtained in Israel. DNA collection
is mentioned explicitly in the patient information. Blood
samples are collected from children with a non-infectious
disease only if blood sampling is required as part of their
routine care. In cases of diarrhoea on enrolment, stool
Table 1 Eligible criteria for Tailored Treatment study
Inclusion criteria Exclusion criteria
Age≥ 1 month Proven or suspected HIV, HBV, or HCV infection
Symptoms ≤8 days Post-transplant
LRTI; ≥ 2 signs Congenital immune deficiency
Respiratory rate > 20/mina Obvious alternative causes of respiratory distress
Chest cough Nosocomial LRTI (> 3 days after hospitalization)
Nasal flaring Other febrile infection during the past 3 weeks
Retractions Active (haematological) malignancy
Rales Immune-suppressive or immune-modulating therapies
Expiratory wheeze Moderate to severe psychomotor retardation
Decreased breath sounds Moderate to severe congenital metabolic disorder
Sepsisb; ≥ 2 signsc
Heartrate > 90/min
Respiratory rate > 20/min
Core body temperature > 38 °C or < 36 °C
White blood cell count > 12,000 cells/ μl or < 4000/ μl
aWHO age-specific criteria for tachypnea will be used for children [41]
bAge-specific criteria for sepsis criteria according to the guidelines of the International Paediatric Sepsis Consensus Conference 2005 will be used for children [42]
cOne of which must be abnormal temperature or white blood cell count
HIV human immunodeficiency virus, HBV hepatitis B virus, HCV hepatitis C virus
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samples are collected. These samples will be evaluated to
identify Clostridium difficile infections.
‘Proteotyping’
Shotgun proteomic detection and identification of mi-
croorganisms, or ‘proteotyping’, relies on recognition of
species-unique peptides by tandem mass spectrometry
(MS), allowing discrimination of species facilitated at
amino acid level resolution. The recent evolution of
mass spectrometers, having high sensitivity, accuracy
and resolution, enables detection of almost the complete
proteome of a microorganism. With such analytical
means, it is feasible to determine directly, within a clin-
ical sample, the species identity, the sub-species strain
type and the factors expressing virulence and antimicro-
bial resistance [35]. Clinical samples are processed by
first removing human biomass and subsequently collect-
ing bacteria. The proteins of the collected bacteria were
processed by the LPI™ FlowCell or in-solution digestion
protocols followed by liquid chromatography tandem
MS (LC-MS/MS) analysis. The recently developed tech-
nology called Lipid-based Protein Immobilization (LPI™)
is based on immobilization of biological material within
a flow cell, followed by digestion of exposed proteins by
an enzyme, such as trypsin [36–38]. The MS-based pro-
teomics methodology has been applied successfully,
without prior cultivations to the analyses of clinical nasal
swab samples from the Sahlgrenska University Hospital
that have been confirmed positive for a respiratory infec-
tious bacterial species, i.e., S. pneumoniae, H. influenza,
M. catarrhalis and S. aureus (unpublished data).
Central database
All clinical data (eCRFs) and research data (host bio-
markers, host microbiome, pathogen identity and resist-
ance) is coded and uploaded to a central, secured
database (HoPOIT database) to which access is granted
only to research partners (Fig. 3). The centralized clin-
ical, microbiological, molecular and biochemical data is
used to develop a multi-parametric model and diagnos-
tic tools for differentiating between bacterial and viral
infections.
Aetiology determination
Currently, no single reference standard exists for differ-
entiating between bacterial and viral aetiology in an
acute infectious disease. Therefore, we follow the Stan-
dards for Reporting of Diagnostic Accuracy (STARD)
recommendation [39], and create a highly rigorous
reference standard based on expert panel adjudication
(Fig. 2). The eCRF of each patient is available to a panel
of three independent physicians that are affiliated to the
country of recruitment. Based on the information in-
cluded in the eCRF, each member of the panel assigns
one of the following diagnostic labels to each one of the
patients: (i) bacterial infection; (ii) viral infection; (iii)
mixed infection (i.e., bacterial and viral co-infection); (iv)
non-infectious disease; or (v) undetermined. Of note,
each expert is blinded to the research results and to the
labels of his peers on the expert panel. For this purpose,
mixed infection (bacterial and viral co-infection) is con-
sidered as bacterial infections, as they often elicit similar
patient management. A final diagnosis is determined
based on consensus agreement between all three experts
Fig. 3 Development of the multi-parametric model
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(Fig. 2). The final diagnosis is used for the purpose of
calculating the accuracy of the newly developed diagnos-
tic tools. Cases with only majority agreement (2 out of 3
experts) are analysed as a separate sub-group. The
remaining cases are labelled as undetermined. Specific-
ally, this label is assigned in cases where each of the
experts assigns a different diagnosis or in cases where 2
or more of the experts assign an “undetermined” diagno-
sis. These patients are used for data analysis and are ex-
pected to comprise roughly 10% of all patients.
Study stages
The study is conducted in two consecutive stages. Stage
A is used to collect molecular, biochemical, microbio-
logical and clinical data on a group of approximately 900
patients. Collected data is used to develop unique diag-
nostic signatures able to distinguish between bacterial
and viral aetiologies, a mass spectrometry based rapid
detection technique for identification of microbial path-
ogens and antimicrobial resistances and a personalized
treatment algorithm for tailored antimicrobial therapy
that integrates clinical, molecular and biochemical
data. In stage B, a second, independent cohort of ap-
proximately 300 patients is recruited for the purpose
of testing and validating the performances of the
multi-parametric model.
Outcomes
Primary endpoint
Sensitivity and specificity for a multi-parametric diag-
nostic model, incorporating different pathogen- and
host-related factors, in differentiating between bacterial
and viral aetiology in patients with LRTI and/or sepsis.
Secondary endpoints
1. Sensitivity and specificity for host-related individual
blood biomarkers, in differentiating between bacter-
ial and viral aetiology from other aetiologist in pa-
tients with LRTI and/or sepsis;
2. Sensitivity and specificity for host-related sets of
blood biomarkers, in differentiating Gram positive
or Gram negative or atypical aetiology from other
disease aetiologist in patients with LRTI and/or
sepsis;
3. Monitoring the temporal dynamics of host-related
blood biomarkers levels during the course of disease
in patients with LRTI and/or sepsis;
4. A list of significant bacterial microbiome
components that are associated with poor or
favourable clinical outcome in patients with LRTI
and/or sepsis;
5. Sensitivity and specificity for liquid
chromatography-mass spectrometry (LC-MS/MS)
and lipid-based Protein Immobilization (LPI)
proteomics-based rapid detection technique in iden-
tifying pathogens in clinical samples of patients with
LRTI and/or sepsis;
6. A web-based application that recommends physi-
cians with a preferred antimicrobial treatment based
on patients clinical, molecular and biochemical
data;
7. To define genetic mechanisms underlying the
different host response between patients with viral
versus bacterial infection.
Sample size calculation
The following power analysis aims to achieve the pri-
mary study objective of developing a new diagnostic
model for classifying patients with viral and bacterial
aetiologist and treatment algorithms to guide antimicro-
bial prescribing.
Paediatric population analysis
First, we estimate the sample size required to reject the
null hypothesis that the sensitivity over the entire popu-
lation, P, is lower than P0 = 70% (H0: P ≤ P0, H1: P > P0)
with significance level of 1% (α = 0.01), power of 80%
(=1-β) for a true sensitivity P1 of 90% (P1 - P0 ≥ 0.2).
For sufficiently large sample sizes (n > ~ 30) the sample
distribution of the sensitivity, is approximately normally
distributed, ( p^ ~ N{P, P(1-P)/n}). Thus, the number of
bacterial patients that are required is:
n ¼ Z1−α
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P0 1−P0ð Þ
p þ Z1−β
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P1 1−P1ð Þ
p
 2
P1−P0ð Þ2
≤76
We estimate that the ratio between bacterial and viral
paediatric patients is 1:3 and that expert consensus is
achieved in 65% of the cases. Thus, the number of pa-
tients with an acute infection required in order to reach
76 bacterial patients is 468 = (76 / 25% / 65%). Using
similar considerations for computing specificity the sam-
ple size for viral patients is also 76. Of note, we antici-
pate that the above mentioned 468 patients will include
229 (= 468 × 75% × 65%) viral patients, and thus there is
no need for additional patients. To assess the
host-response based diagnostics accuracy in differentiat-
ing patients with an acute infection (both viral and bac-
terial) and non-infectious patients, assuming P0 = 70%
(H0: P ≤ P0, H1: P > P0) with significance level of 1% (α
= 0.01), power of 80% (=1-β) for a true sensitivity P1 of
90% (P1 - P0 ≥ 0.2) requires 76 non-infectious patients.
Overall, the paediatric cohort should include at least 468
patients with a suspected infectious disease and 76 pa-
tients with non-infectious.
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Adult population analysis
Using the same model as for the paediatric populations
(assuming α = 0.01, 1-β = 0.2, P1 = 90%, P0 = 70% and a
consensus rate of 65%) and assuming a viral to bacterial
rate of 3:7 yields 390 patients with an infectious disease.
Additionally, 76 non-infectious patients will be enrolled
(based on similar calculations as for the paediatric
population).
Methods for computing the accuracy of a multi-
parametric model
The multi-parametric model integrates various host-re-
lated and pathogen-related parameters into a single
score that determines the likelihood of bacterial and
viral aetiology (Fig. 3). The score is computed using a
multinomial logistic regression formula that is developed
during Stage A of the study. Using predetermined
cut-offs, each of the patients is classified as bacterial,
viral, or inconclusive (i.e., a marginal immune response
that is neither clearly bacterial nor viral). The model
diagnosis will be compared with the consensus diagnosis
in order to determine its accuracy. The diagnostic accur-
acy is quantified by computing the following measures:
sensitivity, specificity, positive predictive value, negative
predictive value, total accuracy, positive likelihood ratio,
negative likelihood ratio and diagnostic odds ratio. The
area under the receiver operation curve is computed to
perform cut-off independent comparisons of different
diagnostic methods.
Discussion and expected results
The inappropriate use of antibiotics has severe global
health and economic consequences, including the emer-
gence of antibiotic-resistant bacteria [33]. A major driver
of antibiotic misuse is the inability to accurately distin-
guish between bacterial and viral infections based on
currently available diagnostic solutions [33]. Many
different biomarkers have been investigated in previous
studies, none of them being accurate enough to establish
or rule out bacterial infections [40]. The TAILORED-
Treatment study is a novel collaboration between (uni-
versity) hospitals, academic institutions and (diagnostic)
industry, aimed to collect and analyse ‘multi-omics’ data
from patients suffering from LRTI and/or sepsis. Univar-
iate and multivariate analysis of the data will generate
new biomarkers to distinguish between bacterial, viral,
and non-infectious disease. The multi-omics approach
to generate infectious disease algorithms utilised by this
study is currently unique within this area of medicine
and provides a template for follow-up combined infec-
tious disease data studies in the future.
Some challenges remain for this type of study. First of
all, as described previously, in a subset of patients, sam-
pling of blood and nasal swabs at two sampling points
(at presentation and after 3–5 days) should allow to
measure data on the temporal dynamics of the
host-pathogen interaction. However, if patients are not
admitted to the hospital or are already discharged after 1
or 2 days, it is hard to collect a second sample. However,
consecutive samples are not necessarily needed in order
to achieve the primary objective. A second challenge is
how to best interpret and efficiently act on the wealth of
data available. Therefore, dedicated bioinformatics pro-
fessionals are part of the TAILORED-Treatment consor-
tium, for building the unique (HoPOIT) database and to
develop the treatment algorithms. Finally, the study is a
non-interventional study, and therefore, the diagnostic
prediction of the model is not used for any clinical, diag-
nostic or prognostic decision making. After completing
the study, utility studies will be needed to establish the
clinical impact of any TAILORED-Treatment algorithms
developed.
In summary, the aim of this prospective international
(TAILORED-Treatment) study is to develop algorithms
to differentiate between bacterial and viral infections in
children and adults with LRTI and/or sepsis. The study
has the potential to improve patient care, reduce un-
necessary antibiotic prescribing (thereby reducing the
spread of antibiotic resistances) and will contribute posi-
tively to institutional, regional and national healthcare
economics.
Additional files
Additional file 1: Questionnaire follow-up. (DOCX 33 kb)
Abbreviations
AE: Adverse events; eCRF: Electronic case record form; ED: Emergency
Department; EMC: Erasmus University Medical Centre Rotterdam;
HAD: Hadassah University Hospital; LRTI: Lower respiratory tract infection;
PCR: Polymerase chain reaction; SIRS: Systemic inflammatory response
syndrome; UMCU: University Medical Centre Utrecht
Acknowledgements
The authors would like to acknowledge the following co-workers on the
TAILORED-Treatment project, who together with the authors are helping to
realize the project goals: Racheli Kreisberg, Vincent Collins, Hans Hoogeveen,
Erik Kristiansson, Anders Karlsson, Astrid Heikema, Deborah Horst-Kreft and
Julio Font Perez.
Funding
The TAILORED-Treatment study received funding from the EU’s Seventh
Framework Programme FP7 under REA grant agreement No. HEALTH-F3–
602860-2013 (TAILORED-Treatment; www.tailored-treatment.eu). The EU
peer-reviewed the protocol and had no further role in the study.
Availability of data and materials
The datasets generated and/or analysed during the current study will be
available to clinicians via a dedicated website (www.TAILORED-Treatment.eu)
and upon request to the study coordinator (J. P. Hays one of the authors of
this article). Datasets may also be available via individual publications and
repositories as results are published by respective TAILORED-Treatment
partners.
van Houten et al. BMC Infectious Diseases  (2018) 18:377 Page 8 of 10
Authors’ contributions
All named authors in this article participated in the TAILORED-Treatment
study and were responsible for formulating the clinical protocol outlined in
this publication, as well as data analysis for the study. All authors have read
and approved this manuscript. JH leaded the consortium and was respon-
sible for the communication regarding the EU. CH, KO, EE, AC, DE and LB
were responsible for the clinical aspects of the protocol, including patient re-
cruitment. SB, RK, RK, YL, AS, EM and JH provided advice on laboratory test-
ing and helped shape the protocol, especially the sample collection section.
DF and EG developed the central database.
Ethics approval and consent to participate
Protocol version 4, date 08–08-2014. Approval for this protocol was obtained
prior to study start from the Medical Ethical Committee of UMCU (14–104,
approval date: 09–09-2014) and the Institutional Review Boards of Hillel Yaffe
Medical Centre (HYMC-0108-13 and HYMC-0107-13), Bnai Zion Medical
Centre (BNZ-0107-14 and BNZ-0011-14) and Hadassah University Medical
Centre (HMO-0007-14 and HMO-0006-14). Written, informed consent will be
obtained from each patient-participant by research staff (by research nurse,
research fellow or the principal investigator) prior to enrolment in the study.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Paediatric Immunology and Infectious Diseases, University
Medical Centre Utrecht, Utrecht University, Office KC.03.063.0, P.O. Box 85090,
3508 AB Utrecht, The Netherlands. 2MeMed, Tirat Carmel, Israel. 3Division of
Paediatric Infectious Disease Unit, Hadassah-Hebrew University Medical
Centre, Jerusalem, Israel. 4Department of Medical Microbiology and
Infectious Diseases, Erasmus University Medical Centre (Erasmus MC),
Rotterdam, the Netherlands. 5Department of Internal Medicine, Erasmus
University Medical Centre (Erasmus MC), Rotterdam, the Netherlands.
6Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska
Academy, University of Gothenburg, Gothenburg, Sweden. 7Noray
Bioinformatics, Derio, Spain. 8Department of Pathology, Clinical
Bioinformatics Unit, Erasmus University Medical Centre (Erasmus MC),
Rotterdam, the Netherlands. 9University of Gothenburg, Gothenburg,
Sweden.
Received: 20 June 2018 Accepted: 1 August 2018
References
1. Get Smart: Fast facts about antibiotic resistance. [https://www.cdc.gov/
antibiotic-use/community/about/fast-facts.html].
2. Davey P, Brown E, Fenelon L, Finch R, Gould I, Holmes A, Ramsay C, Taylor
E, Wiffen P, Wilcox M. Systematic review of antimicrobial drug prescribing in
hospitals. Emerg Infect Dis. 2006;12(2):211–6.
3. Linder JA, Stafford RS. Antibiotic treatment of adults with sore throat by
community primary care physicians: a national survey, 1989-1999. JAMA.
2001;286(10):1181–6.
4. Pulcini C, Cua E, Lieutier F, Landraud L, Dellamonica P, Roger PM. Antibiotic
misuse: a prospective clinical audit in a French university hospital. Eur J Clin
Microbiol Infect Dis. 2007;26(4):277–80.
5. Cadieux G, Tamblyn R, Dauphinee D, Libman M. Predictors of inappropriate
antibiotic prescribing among primary care physicians. CMAJ. 2007;177(8):
877–83.
6. Antibiotic Use in the United States, 2017: Progress and Opportunities
[https://www.cdc.gov/antibiotic-use/stewardship-report/outpatient.html ].
7. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med.
2002;346(5):334–9.
8. About Antimicrobial Resistance [https://www.cdc.gov/drugresistance/
about.html].
9. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century--a clinical
super-challenge. N Engl J Med. 2009;360(5):439–43.
10. Battle of the Bugs: Fighting Antibiotic Resistance [https://www.fda.gov/
drugs/resourcesforyou/consumers/ucm143568.htm].
11. Review on Antimicrobial Resistance: Tackling drug-resistant infections
globally: final report and recommendations. [https://amr-review.org/sites/
default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%
20for%20the%20health%20and%20wealth%20of%20nations_1.pdf].
12. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and
appropriate antibiotic selection reduce length of hospital stay of patients
with community-acquired pneumonia: link between quality of care and
resource utilization. Arch Intern Med. 2002;162(6):682–8.
13. Craig JC, Williams GJ, Jones M, Codarini M, Macaskill P, Hayen A, Irwig L,
Fitzgerald DA, Isaacs D, McCaskill M. The accuracy of clinical symptoms and
signs for the diagnosis of serious bacterial infection in young febrile
children: prospective cohort study of 15 781 febrile illnesses. BMJ. 2010;340:
c1594.
14. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic
administration and outcomes for Medicare patients hospitalized with
community-acquired pneumonia. Arch Intern Med. 2004;164(6):637–44.
15. Houck PM, Bratzler DW, Niederman M, Bartlett JG. Pneumonia treatment
process and quality. Arch Intern Med. 2002;162(7):843–4.
16. De Miguel-Yanes JM, Andueza-Lillo JA, Gonzalez-Ramallo VJ, Pastor L,
Munoz J. Failure to implement evidence-based clinical guidelines for sepsis
at the ED. Am J Emerg Med. 2006;24(5):553–9.
17. Metersky ML, Sweeney TA, Getzow MB, Siddiqui F, Nsa W, Bratzler DW.
Antibiotic timing and diagnostic uncertainty in Medicare patients with
pneumonia: is it reasonable to expect all patients to receive antibiotics
within 4 hours? Chest. 2006;130(1):16–21.
18. Little PS, Williamson I. Are antibiotics appropriate for sore throats? Costs
outweigh the benefits. Bmj. 1994;309(6960):1010–1.
19. Spiro DM, Tay KY, Arnold DH, Dziura JD, Baker MD, Shapiro ED. Wait-and-see
prescription for the treatment of acute otitis media: a randomized
controlled trial. Jama. 2006;296(10):1235–41.
20. Little P. Delayed prescribing of antibiotics for upper respiratory tract
infection. Bmj. 2005;331(7512):301–2.
21. Zwart S, Sachs AP, Ruijs GJ, Gubbels JW, Hoes AW, de Melker RA. Penicillin
for acute sore throat: randomised double blind trial of seven days versus
three days treatment or placebo in adults. Bmj. 2000;320(7228):150–4.
22. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of
non-influenza-related viral respiratory tract infection in the United States.
Arch Intern Med. 2003;163(4):487–94.
23. John JF Jr, Fishman NO. Programmatic role of the infectious diseases
physician in controlling antimicrobial costs in the hospital. Clin Infect Dis.
1997;24(3):471–85.
24. Study: Antibiotics problems cost U.S. between $17B and $26B a year [http://
www.bizjournals.com/triangle/stories/2009/10/19/daily4.html].
25. Roberts RR, Hota B, Ahmad I, Scott RD 2nd, Foster SD, Abbasi F, Schabowski
S, Kampe LM, Ciavarella GG, Supino M, et al. Hospital and societal costs of
antimicrobial-resistant infections in a Chicago teaching hospital:
implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–84.
26. Antibiotic resistance - Frequently asked question [http://www.euro.who.int/
en/health-topics/disease-prevention/antimicrobial-resistance/antibiotic-
resistance/frequently-asked-questions].
27. Gerber JS, Ross RK, Bryan M, Localio AR, Szymczak JE, Wasserman R,
Barkman D, Odeniyi F, Conaboy K, Bell L, et al. Association of Broad- vs
narrow-Spectrum antibiotics with treatment failure, adverse events, and
quality of life in children with acute respiratory tract infections. Jama. 2017;
318(23):2325–36.
28. Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The impact of timing
of antibiotics on outcomes in severe sepsis and septic shock: a systematic
review and meta-analysis. Crit Care Med. 2015;43(9):1907–15.
29. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky
JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving sepsis campaign:
international guidelines for management of severe sepsis and septic shock:
2012. Crit Care Med. 2013;41(2):580–637.
30. Greenberg D, Broides A, Blancovich I, Peled N, Givon-Lavi N, Dagan R.
Relative importance of nasopharyngeal versus oropharyngeal sampling
for isolation of Streptococcus pneumoniae and Haemophilus influenzae
from healthy and sick individuals varies with age. J Clin Microbiol. 2004;
42(10):4604–9.
van Houten et al. BMC Infectious Diseases  (2018) 18:377 Page 9 of 10
31. Rhedin S, Lindstrand A, Rotzen-Ostlund M, Tolfvenstam T, Ohrmalm L,
Rinder MR, Zweygberg-Wirgart B, Ortqvist A, Henriques-Normark B, Broliden
K, et al. Clinical utility of PCR for common viruses in acute respiratory illness.
Pediatrics. 2014;133(3):e538–45.
32. Cruz AT, Demmler-Harrison GJ, Caviness AC, Buffone GJ, Revell PA.
Performance of a rapid influenza test in children during the H1N1 2009
influenza a outbreak. Pediatrics. 2010;125(3):e645–50.
33. Cohen A, Bont L, Engelhard D, Moore E, Fernandez D, Kreisberg-Greenblatt R,
Oved K, Eden E, Hays JP. A multifaceted ‘omics’ approach for addressing the
challenge of antimicrobial resistance. Future Microbiol. 2015;10(3):365–76.
34. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal
SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS international
Sepsis definitions conference. Intensive Care Med. 2003;29(4):530–8.
35. Karlsson R, Gonzales-Siles L, Boulund F, Svensson-Stadler L, Skovbjerg S,
Karlsson A, Davidson M, Hulth S, Kristiansson E, Moore ER. Proteotyping:
proteomic characterization, classification and identification of
microorganisms--a prospectus. Syst Appl Microbiol. 2015;38(4):246–57.
36. Karlsson R, Davidson M, Svensson-Stadler L, Karlsson A, Olesen K, Carlsohn E,
Moore ER. Strain-level typing and identification of bacteria using mass
spectrometry-based proteomics. J Proteome Res. 2012;11(5):2710–20.
37. Gonzales-Siles L, Karlsson R, Kenny D, Karlsson A, Sjoling A. Proteomic
analysis of enterotoxigenic Escherichia coli (ETEC) in neutral and alkaline
conditions. BMC Microbiol. 2017;17(1):11.
38. Karlsson R, Thorell K, Hosseini S, Kenny D, Sihlbom C, Sjoling A, Karlsson A,
Nookaew I. Comparative analysis of two helicobacter pylori strains using
genomics and mass spectrometry-based proteomics. Front Microbiol. 2016;
7:1757.
39. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L,
Levine D, Reitsma JB, de Vet HC, et al. STARD 2015 guidelines for reporting
diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;
6(11):e012799.
40. Kapasi AJ, Dittrich S, Gonzalez IJ, Rodwell TC. Host biomarkers for
distinguishing bacterial from non-bacterial causes of acute febrile illness: a
comprehensive review. PLoS One. 2016;11(8):e0160278.
41. Organization WH. Pocket book of Hospital Care for Children. Geneva,
Switzerland: World Health Organization; 2005.
42. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus
conference: definitions for sepsis and organ dysfunction in pediatrics.
Pediatr Crit Care Med. 2005;6(1):2–8.
van Houten et al. BMC Infectious Diseases  (2018) 18:377 Page 10 of 10
